Page 2 - இந்‌ஸ்டிடூடோ டி மருத்துவ மூலக்கூறு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vumerity Linked to Better Quality of Life Than Tecfidera in RRMS Trial 4.4 (9) Vumerity (diroximel fumarate) is easier on the gastrointestinal tract than Tecfidera (dimethyl fumarate), and this translates into better quality of life for patients with relapsing-remitting multiple sclerosis (RRMS), a new analysis of EVOLVE-MS-2 trial data has found. The study, “ Vumerity (previously BIIB098 and ALKS8700) is an oral delayed-release capsule marketed by Biogen that is approved for the treatment of relapsing forms of multiple sclerosis in adults. It has the same active metabolite (product resulting from the body’s chemical processes) as Tecfidera another approved oral medicine for relapsing forms of multiple sclerosis, also marketed by Biogen.

Leiden university medical centerTherapeutic advancesMedical microbiologyInfectious diseasesApplied biologyInstituto de medicina molecularமருத்துவ நுண்ணுயிரியல்தொற்று நோய்கள்பயன்படுத்தப்பட்டது உயிரியல்இந்‌ஸ்டிடூடோ டி மருத்துவ மூலக்கூறு